Literature DB >> 21784540

Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan.

Zoltán Papp1, István Édes, Sonja Fruhwald, Stefan G De Hert, Markku Salmenperä, Heli Leppikangas, Alexandre Mebazaa, Giovanni Landoni, Elena Grossini, Philippe Caimmi, Andrea Morelli, Fabio Guarracino, Robert H G Schwinger, Sven Meyer, Lars Algotsson, Bernt Gerhard Wikström, Kirsten Jörgensen, Gerasimos Filippatos, John T Parissis, Martín J García González, Alexander Parkhomenko, Mehmet Birhan Yilmaz, Matti Kivikko, Piero Pollesello, Ferenc Follath.   

Abstract

The molecular background of the Ca(2+)-sensitizing effect of levosimendan relates to its specific interaction with the Ca(2+)-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K(+) channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K(+) channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784540     DOI: 10.1016/j.ijcard.2011.07.022

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  83 in total

Review 1.  [Management of patients with pulmonary hypertension].

Authors:  B Preckel; S Eberl; J Fräßdorf; M W Hollmann
Journal:  Anaesthesist       Date:  2012-07       Impact factor: 1.041

2.  Fluorescence Based Characterization of Calcium Sensitizer Action on the Troponin Complex.

Authors:  William Schlecht; King-Lun Li; Dehong Hu; Wenji Dong
Journal:  Chem Biol Drug Des       Date:  2015-09-16       Impact factor: 2.817

3.  Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure.

Authors:  Kristin Wilson; Anuradha Guggilam; T Aaron West; Xiaojin Zhang; Aaron J Trask; Mary J Cismowski; Pieter de Tombe; Sakthivel Sadayappan; Pamela A Lucchesi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-26       Impact factor: 4.733

4.  Understanding the differences among inotropes.

Authors:  Mattia Arrigo; Alexandre Mebazaa
Journal:  Intensive Care Med       Date:  2015-01-21       Impact factor: 17.440

Review 5.  Targeting the sarcomere to correct muscle function.

Authors:  Peter M Hwang; Brian D Sykes
Journal:  Nat Rev Drug Discov       Date:  2015-04-17       Impact factor: 84.694

6.  Prevention of organ dysfunction in septic shock: still looking for an effective treatment.

Authors:  Giovanni Landoni; Alessandro Belletti; Alessandro Putzu; Alberto Zangrillo
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

7.  Successful Identification of Cardiac Troponin Calcium Sensitizers Using a Combination of Virtual Screening and ROC Analysis of Known Troponin C Binders.

Authors:  Melanie L Aprahamian; Svetlana B Tikunova; Morgan V Price; Andres F Cuesta; Jonathan P Davis; Steffen Lindert
Journal:  J Chem Inf Model       Date:  2017-11-16       Impact factor: 4.956

8.  Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery.

Authors:  K Distelmaier; C Roth; L Schrutka; C Binder; B Steinlechner; G Heinz; I M Lang; G Maurer; H Koinig; A Niessner; M Hülsmann; W Speidl; G Goliasch
Journal:  Br J Anaesth       Date:  2016-07       Impact factor: 9.166

9.  Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.

Authors:  Bernard Cholley; Thibaut Caruba; Sandrine Grosjean; Julien Amour; Alexandre Ouattara; Judith Villacorta; Bertrand Miguet; Patrick Guinet; François Lévy; Pierre Squara; Nora Aït Hamou; Aude Carillion; Julie Boyer; Marie-Fazia Boughenou; Sebastien Rosier; Emmanuel Robin; Mihail Radutoiu; Michel Durand; Catherine Guidon; Olivier Desebbe; Anaïs Charles-Nelson; Philippe Menasché; Bertrand Rozec; Claude Girard; Jean-Luc Fellahi; Romain Pirracchio; Gilles Chatellier
Journal:  JAMA       Date:  2017-08-08       Impact factor: 56.272

Review 10.  Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.

Authors:  Simona Silvetti; Teresa Greco; Ambra Licia Di Prima; Marta Mucchetti; Castro Maria de Lurdes; Laura Pasin; Mara Scandroglio; Giovanni Landoni; Alberto Zangrillo
Journal:  Clin Res Cardiol       Date:  2013-12-25       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.